Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Philip Philip, MD, talks about treating a newly diagnosed stage 4 pancreatic cancer patient

Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, talks about some considerations when treating a newly diagnosed stage 4 pancreatic cancer patient

Published: 24 January 2017

Recent Videos: ASCO GI Conference Coverage

video

Philip Philip, MD, shares his perspective on using TAS-102 and regorafenib in CRC patients

Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, shares his perspective on how to use both TAS-102 and ...

video

Philip Philip, MD, on integrating immunotherapy into existing treatment regimens for CRC patients

Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, on integrating immunotherapy into existing treatment regimens for CRC patients

video

Philip Philip, MD, talks about treating a newly diagnosed stage 4 pancreatic cancer patient

Dr. Philip, Professor of Oncology and Pharmacology, Karmanos Cancer Institute, talks about some considerations when treating a newly diagnosed stage ...

video

Thomas A. Abrams, MD, on reliably identifying subgroups of patients for targeted therapies in HCC

Dr. Abrams, Senior Physician, Dana-Farber Cancer Institute, on reliably identifying subgroups of patients for targeted therapies in HCC

video

Jonathan R. Strosberg, MD, discusses the quality of life data from the NETTER-1 study

Dr. Strosberg, MD, Associate Professor, Moffitt Cancer Center, discusses the quality of life data from the NETTER-1 study

video

John L. Marshall, MD, tells us how vaccines can be used to broaden the use of immunotherapies

Dr. Marshall, Chief, Hematology and Oncology, Lombardi Comprehensive Cancer Center, tells us how vaccines can be used to broaden the ...

video

Jonathan R. Strosberg, MD, discusses the results of the NETTER-1 study

Dr. Strosberg, MD, Associate Professor, Moffitt Cancer Center, discusses the results of the NETTER-1 study

video

Thomas A. Abrams, MD, on how checkpoint inhibitors will be incorporated into treatment of HCC

Dr. Abrams, Senior Physician, Dana-Farber Cancer Institute, on how checkpoint inhibitors will be incorporated into the treatment of unresectable HCC

video

Alan P. Venook, MD, explains how the 80405 study and its impact on treatment guidelines

Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, explains how the 80405 study in CRC ...

video

Alan P. Venook, MD, on integrating immunotherapy into treatment regimens for gastric cancer patients

Dr. Venook, Professor, Department of Medicine, UCSF Helen Diller Family Comprehensive Cancer Center, on integrating immunotherapy into existing treatment regimens ...

Related Videos

video-image

Philip Philip, MD, reflects on the impact of PEGPH20 in met pancreatic cancer

video-image

Jonathan R. Strosberg, MD, discusses the results of the NETTER-1 study

video-image

Jonathan R. Strosberg, MD, discusses the quality of life data from the NETTER-1 study

video-image

John L. Marshall, MD, talks about the results of the RESORCE trial

video-image

John L. Marshall, MD, discusses which molecular tests to order when determining treatment approach

video-image

John L. Marshall, MD, on how to integrate genetic mutations into a treatment decision

video-image

John L. Marshall, MD, on how checkpoint inhibitors are being integrated into treatment of GI cancers

video-image

John L. Marshall, MD, tells us how vaccines can be used to broaden the use of immunotherapies

video-image

Jeffrey A. Meyerhardt, MD, talks about the DFCI wellness study

video-image

Philip Philip, MD, talks about treating a newly diagnosed stage 4 pancreatic cancer patient

video-image

Philip Philip, MD, on whether resected pancreatic cancer patients should be offered adjuvant therapy

video-image

Philip Philip, MD, shares his perspective on using TAS-102 and regorafenib in CRC patients

video-image

Philip Philip, MD, on which molecular tests to order for a newly diagnosed CRC patient

video-image

Philip Philip, MD, on integrating immunotherapy into existing treatment regimens for CRC patients

video-image

Alan P. Venook, MD, explains how the 80405 study and its impact on treatment guidelines

video-image

Alan P. Venook, MD, discusses which molecular tests to order for a newly diagnosed CRC patient

video-image

Alan P. Venook, MD, provides his perspective on using TAS-102 and regorafenib in CRC patients

video-image

Alan P. Venook, MD, on identifying subgroups of HCC patients that are likely to respond to therapy

video-image

Alan P. Venook, MD, on if the RESORCE trial will change the role of regorafenib

video-image

Alan P. Venook, MD, on integrating immunotherapy into treatment regimens for gastric cancer patients

video-image

Alan P. Venook, MD, on integrating immunotherapy into existing treatment regimens for HCC patients

video-image

Alan P. Venook, MD, on integrating immunotherapy into existing treatment regimens for CRC patients

video-image

Thomas A. Abrams, MD, on how checkpoint inhibitors will be incorporated into treatment of HCC

video-image

Thomas A. Abrams, MD, on reliably identifying subgroups of patients for targeted therapies in HCC

video-image

Thomas A. Abrams, MD, on whether physicians will incorporate regorafenib into clinical practice

video-image

Thomas A. Abrams, MD, discusses the outcomes of the RESORCE trial as presented here at ASCO GI 2017

video-image

Thomas A. Abrams, MD, on how new agents being studied for HCC will be integrated into the treatment

video-image

Howard S. Hochster, MD, on integrating immunotherapy into treatment regimens for GI cancer patients

video-image

Howard S. Hochster, MD, explains the outcomes of the phase 2 study in BRAF mutated CRC patients

video-image

Howard S. Hochster, MD, discusses if genetic profiling has changed treating CRC patients

video-image

Howard S. Hochster, MD, provides perspective on how to use TAS-102 and regorafenib in CRC patients

video-image

Howard S. Hochster, MD, differentiates regorafenib from 5FU and TAS-102

video-image

Ghassan Abou-Alfa, MD, discusses how checkpoint inhibitors be incorporated into the treatment

video-image

Ghassan Abou-Alfa, MD, on identifying subgroups of patients for targeted therapies in HCC

video-image

Ghassan Abou-Alfa, MD, discusses if regorafenib will be incorporated into clinical practice

video-image

Ghassan Abou-Alfa, MD, discusses the outcomes of the RESORCE trial

video-image

Ghassan Abou-Alfa, MD, explains how new agents in advanced HCC are being integrated into treatment

video-image

Nevena Damjanov, MD, explains how checkpoint inhibitors will be incorporated into the treatment

video-image

Nevena Damjanov, MD, discusses identifying subgroups of patients for targeted therapies in HCC

video-image

Nevena Damjanov, MD, on whether regorafenib will be integrated into clinical practice

video-image

Nevena Damjanov, MD, explains the outcomes of the RESORCE trial as presented here at ASCO GI 2017

video-image

Nevena Damjanov, MD, discusses how new agents for advanced HCC will be integrated into the treatment

video-image

Johanna Bendell, MD, talks about the Proprietary Neoantigen Identification Technology platform

video-image

Johanna Bendell, MD, discusses the RESORCE trial data

video-image

Johanna Bendell, MD, discusses some of the challenges in treating pancreatic cancer

video-image

Johanna Bendell, MD, on some of the exciting trials or drugs in development in pancreatic cancer

video-image

Johanna Bendell, MD, talks about the phase 3 study in advanced gastric or GE junction presented at ASCO GI 2017

video-image

Jeffrey A. Meyerhardt, MD, discusses outcomes of the phase 2 study in BRAF mutated CRC patients

video-image

Jeffrey A. Meyerhardt, MD, explains which molecular tests help determine treatment approach

video-image

Jeffrey A. Meyerhardt, MD, on integrating immunotherapy into treatment regimens for GI cancer

video-image

Edith P. Mitchell, MD, discusses the goals of the NCI-MATCH trial and the progress to date

video-image

Edith P. Mitchell, MD, on how the Blue Ribbon Panel may help with the Cancer Moonshot initiative

video-image

Edith P. Mitchell, MD, discusses integrating immunotherapy into treatment regimens for CRC patients

video-image

Edith P. Mitchell, MD, explains how organoids are being used for cancer biology research